

**A Tale of Two Reports:**

# **The Aggregate Report**

**Monica Youngblood, MPH, M(ASCP)**

Laboratory Consultant  
Laboratory Capacity Team (LCT)/DTBE  
[myoungblood@cdc.gov](mailto:myoungblood@cdc.gov)

10<sup>th</sup> APHL National Laboratory Aspects of Tuberculosis Meeting  
April, 2017

## **Overview**

- ❑ Purpose of the Aggregate Report**
- ❑ How to Use the Aggregate Report**
- ❑ National Workload Data**
- ❑ MTBC Culture Positivity**
- ❑ Turn Around Time Indicators**
- ❑ National TB Surveillance and Self-Reported Data**
- ❑ Current Methods**

# **Background and Purpose of Aggregate Report**

- ❑ Published in 2010, 2011, 2014, and 2017**
- ❑ Uses self-reported data from CDC TB Elimination Cooperative Agreement narratives**
- ❑ Comparison of aggregate workload data**
- ❑ NAAT usage**
- ❑ PHL TAT trends**
- ❑ Testing methods**
- ❑ Provides data back to the grantees**
- ❑ Useful for assessing benchmarks and peer comparisons**


## **How to Use the Aggregate Report**

- ❑ Monitor workload and TAT indicators in your laboratory**
- ❑ Evaluate against peer data**
- ❑ Track progress and set goals**
- ❑ Examine national average and trends**


## National Workload Data, 2012-2015

	Four Year Change No. (% change)
<b>Clinical specimens<sup>a</sup> received</b>	-30,743 (-12.9)
<b>Patients for whom a specimen was submitted<sup>b</sup></b>	-11,306 (-10.9)
<b>Patients culture positive for MTBC</b>	-402 (-9.4)
<b>Patients for whom a reference isolate was submitted<sup>c</sup></b>	-2,179 (-12.1)
<b>Patients with a reference isolate identified as MTBC</b>	323 (10.8)
<b>Patients for whom DST was performed</b>	-848 (-12.4)
<b>Patients tested by NAAT or other rapid test</b>	5,813 (39.5)
<b>Patients NAAT positive for MTBC</b>	199 (6.5)
<b>IGRA</b>	5,551 (6.5) <sup>d</sup>


# Overview of Specimens Processed and Patients Tested



# Overview of DSTs and NAATs




# NAAT in the Public Health Laboratory






# Distribution of PHL Testing Volumes Measured by Total Number of Clinical Specimens Received, 2015



\*These jurisdictions referred all TB testing to another laboratory.

# MTBC Culture Positivity, 2015

- Wide range of culture positivity in PHLs
- National percentage is the percent of all patient specimens received in PHL in 2015 that were positive for MTBC in culture
- Determine your baseline MTBC culture positivity and monitor your own percentage over time




# Turnaround Time Indicators, 2015


	Benchmark			
	Specimen receipt within 1 day of collection	AFB smear result within 1 day of receipt	ID of MTBC within 21 days of receipt	DST within 17 days of ID of MTBC
<b>National Target (% of specimens that should meet benchmark)</b>	<b>67%</b>	<b>92%</b>	<b>74%</b>	<b>69%</b>
<b>No. laboratories meeting or exceeding National Target*</b>	<b>12</b>	<b>31</b>	<b>25</b>	<b>20†</b>
<b>National average* (% of specimens meeting benchmark)</b>	<b>45%</b>	<b>90%</b>	<b>69%</b>	<b>61%</b>
<b>No. laboratories meeting or exceeding national average*</b>	<b>31</b>	<b>33</b>	<b>29</b>	<b>26†</b>

\*Number of laboratories reporting = 57. †10 PHL referring isolates to the DST Reference Center for first-line DST are excluded from analysis of the DST TAT for 2015.

# Trends in NAAT, 2012 – 2015




# Specimen Receipt TAT Comparison by Courier Availability, 2015




## Comparison of National TB Surveillance Data and PHL Self-Reported Data, 2012 – 2015

		Year			
		2012	2013	2014	2015
<b>National TB Surveillance data</b>	<b>Total no. TB cases</b>	9,945	9,565	9,421	9,557
	<b>No. culture-confirmed TB cases</b>	7,598	7,358	7,226	7,410
	<b>No. culture-confirmed TB cases with DST reported</b>	7,250	7,108	6,949	7,209
<b>Self-reported PHL data (n=58 PHL reporting)</b>	<b>No. NAAT positive MTBC patients (% of culture-confirmed TB cases as reported for national surveillance)</b>	3,045 (40%)	2,918 (40%)	2,631 (36%)	3,244 (44%)
	<b>No. MTBC culture-positive patients (% of culture-confirmed TB cases as reported for national surveillance)</b>	4,270 (56%)	4,201 (57%)	3,748 (52%)	3,868 (52%)
	<b>No. patient DST performed (% of culture-confirmed TB cases as reported for national surveillance)</b>	6,854 (95%)	6,434 (91%)	5,929 (85%)	6,006 (83%)

# NAAT Methods, 2016




# Primary ID Methods, 2016






# First-line DST Methods, 2016



# IGRA Methods, 2016



# Final Thoughts

- ❑ Monitor data and compare it to data from other states and national averages
- ❑ Freely available on the internet: <https://www.cdc.gov/tb/publications/reportsarticles/labreports.htm>
- ❑ Copies of 4th Edition Aggregate Report
- ❑ National and state data sheets



# Questions?



**For more information please contact Centers for Disease Control and Prevention**

1600 Clifton Road NE, Atlanta, GA 30329

Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: [cdcinfo@cdc.gov](mailto:cdcinfo@cdc.gov) Web: <http://www.cdc.gov>

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.